{ "schemaVersion": 2, "eyebrow": "Gastroenterology", "title": "Barrett Esophagus", "summary": "Manage Barrett esophagus by confirming intestinal metaplasia and dysplasia with high-quality endoscopy and expert pathology, then selecting surveillance or eradication therapy according to dysplasia grade, visible lesions, and procedural fitness.", "seoDescription": "Physician guide to Barrett esophagus screening, Seattle biopsy surveillance, dysplasia confirmation, endoscopic eradication therapy, and follow-up.", "clinicalQuestion": "How should Barrett esophagus be screened, sampled, risk-stratified, treated, and surveilled according to dysplasia status?", "specialty": "Gastroenterology", "audience": "U.S. physicians and medical trainees", "tags": [ "Barrett esophagus", "Seattle protocol", "Barrett dysplasia", "radiofrequency ablation", "endoscopic eradication therapy", "esophageal adenocarcinoma" ], "keyTakeaways": [ "Screen once with upper endoscopy in chronic GERD plus at least 3 additional risk factors: male sex, age over 50 years, White race, tobacco smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. [14]", "At surveillance, inspect with high-definition white light and chromoendoscopy, biopsy every visible lesion separately, and use systematic 4-quadrant Seattle biopsies. [14][18]", "Have any diagnosis of Barrett dysplasia confirmed by a second gastrointestinal pathologist before changing surveillance or performing eradication therapy. [14][18]", "Do not perform routine endoscopic eradication therapy for nondysplastic Barrett esophagus; surveillance is the preferred approach. [5][20]", "For confirmed low-grade dysplasia, radiofrequency ablation is favored after reproducible dysplasia on biopsies from 2 endoscopies and confirmation by 2 gastrointestinal pathologists. [1][18]", "A visible nodular lesion requires endoscopic resection before ablation of residual Barrett mucosa; high-grade dysplasia generally warrants endoscopic eradication rather than surveillance alone. [2][18]" ], "sections": [ { "id": "screening-and-diagnosis", "eyebrow": "Case finding", "heading": "Who should undergo screening endoscopy?", "intro": "Use risk-enriched screening rather than endoscopy for reflux symptoms alone.", "paragraphs": [ "Offer a single screening endoscopy to patients with chronic GERD symptoms who also have 3 or more additional Barrett esophagus risk factors: male sex, age greater than 50 years, White race, tobacco smoking, obesity, or a first-degree family history of Barrett esophagus or esophageal adenocarcinoma. [14]", "Do not place patients with an irregular Z-line or columnar-lined esophagus shorter than 1 cm into a Barrett surveillance program. AGA guidance conditionally recommends against surveillance for columnar-lined esophagus shorter than 1 cm, and NICE recommends no surveillance for confirmed short-segment Barrett esophagus under 3 cm without intestinal metaplasia after 2 endoscopies. [8][18]", "During diagnostic endoscopy, document Barrett extent with the Prague C&M classification and obtain at least 8 biopsies when endoscopic findings suggest Barrett esophagus; use the Seattle protocol for segments longer than 4 cm. [14]" ], "bullets": [ "Define the distal Barrett landmark at the proximal gastric folds; report circumferential and maximal extent separately with Prague C&M criteria. [16]", "Sample any nodule, ulcer, mass, or other mucosal irregularity separately because visible abnormalities have increased likelihood of dysplasia or early cancer. [15]", "Control reflux-related inflammation before surveillance biopsies when feasible, because reactive atypia can confound dysplasia interpretation. [17]" ], "subsections": [], "table": { "caption": "Screening and diagnostic decisions in suspected Barrett esophagus. [14][18]", "columns": [ "Endoscopic or clinical finding", "Interpretation", "Next action" ], "rows": [ [ "Chronic GERD plus 3 or more specified risk factors", "Risk-enriched candidate for screening. [14]", "Perform one screening upper endoscopy. [14]" ], [ "Columnar mucosa <1 cm or irregular Z-line", "Does not warrant routine Barrett surveillance. [8]", "Do not enroll in surveillance solely for this finding. [8]" ], [ "Possible Barrett mucosa at screening", "Histology is needed to establish intestinal metaplasia. [14]", "Obtain at least 8 biopsies; use Seattle sampling for segments >4 cm. [14]" ], [ "Visible lesion within Barrett segment", "Higher-risk focal neoplasia must be excluded. [15]", "Target and separately label biopsies; if neoplasia is identified, plan endoscopic resection for visible lesions. [2]" ] ] } }, { "id": "surveillance-technique-and-pathology", "eyebrow": "Risk stratification", "heading": "How to perform surveillance and validate dysplasia", "intro": "Surveillance quality determines whether dysplasia classification is actionable.", "paragraphs": [ "Use high-resolution white-light endoscopy plus chromoendoscopy, including virtual chromoendoscopy, for Barrett surveillance. Perform targeted biopsies from visible lesions, then systematic 4-quadrant biopsies every 2 cm in patients without prior dysplasia and every 1 cm when there is a history of dysplasia. [10][14]", "The Seattle protocol consists of careful inspection, biopsy of visible lesions, and 4-quadrant biopsies at intervals no greater than 2 cm from the lower esophageal sphincter to the squamocolumnar junction. Its purpose is to reduce sampling error because dysplasia can be focal and endoscopically inconspicuous. [14]", "Before labeling a patient low-grade dysplasia, high-grade dysplasia, or indefinite for dysplasia, obtain confirmation from a second pathologist with gastrointestinal pathology expertise. This is a strong ACG recommendation for dysplasia of any grade and is particularly consequential because the diagnosis determines whether the patient enters ablation therapy. [14]" ], "bullets": [ "Use 1-cm rather than 2-cm 4-quadrant mapping in a dysplastic Barrett segment. [10][17]", "Biopsy the anatomic cardia separately during mapping surveillance when following the described protocol. [17]", "Post-eradication surveillance should examine both esophagus and cardia with white light, virtual chromoendoscopy, and near focus. [11]" ], "subsections": [ { "heading": "Indefinite for dysplasia", "paragraphs": [ "For indefinite dysplasia, optimize acid-suppressive therapy and repeat upper endoscopy with biopsies in 6 months. If repeat biopsies do not show definite dysplasia, revert to the nondysplastic Barrett surveillance strategy. [18][19]" ], "bullets": [] } ], "table": { "caption": "Biopsy strategy by Barrett dysplasia context. [10][14][17]", "columns": [ "Clinical context", "Inspection and biopsy approach", "Actionable implication" ], "rows": [ [ "Nondysplastic Barrett surveillance", "High-definition white light plus chromoendoscopy; targeted lesion biopsies plus 4-quadrant biopsies every 2 cm. [10][14]", "Detect occult dysplasia while continuing surveillance-based management. [12]" ], [ "Prior or suspected dysplasia", "Target visible lesions and obtain 4-quadrant biopsies every 1 cm. [10][17]", "Confirm grade with expert gastrointestinal pathology before treatment selection. [14]" ], [ "Indefinite for dysplasia", "Optimize acid suppression and repeat endoscopy at 6 months. [18][19]", "Definite dysplasia redirects to eradication therapy planning; no definite dysplasia redirects to nondysplastic surveillance. [19]" ] ] } }, { "id": "management-by-dysplasia-grade", "eyebrow": "Endoscopic management", "heading": "Choose surveillance or eradication therapy by dysplasia grade and lesion morphology", "intro": "Visible lesions require resection-first management; flat dysplasia is generally treated with ablation.", "paragraphs": [ "For nondysplastic Barrett esophagus, use endoscopic surveillance rather than routine endoscopic eradication therapy. RFA is not suggested for the general population without dysplasia because comparative evidence has not established a superior net health outcome over surveillance. [5][20]", "For confirmed low-grade dysplasia, discuss endoscopic eradication therapy versus surveillance, but favor RFA when dysplasia is confirmed on biopsies from 2 separate endoscopies and by 2 gastrointestinal pathologists. Randomized evidence shows RFA improves complete eradication of dysplasia and intestinal metaplasia compared with surveillance and shows benefit for progression to high-grade dysplasia or cancer, although progression estimates are imprecise. [1][18][21]", "For high-grade dysplasia, proceed with endoscopic eradication therapy rather than surveillance as first-line management. If a visible lesion is present, perform endoscopic resection, typically EMR, for staging and therapy, then ablate residual Barrett mucosa. NICE specifically recommends ablation of residual Barrett esophagus after endoscopic resection for high-grade dysplasia. [2][18]" ], "bullets": [ "Use EMR for a visible nodular lesion or early esophageal adenocarcinoma rather than primary ablation of that lesion. [2][3]", "Use RFA as the established ablation modality for dysplastic Barrett esophagus; cryotherapy and photodynamic therapy may be alternatives or adjuncts when resection is unsuitable or another modality is needed. [6]", "Refer long-segment Barrett esophagus of 10 cm or more to an expert Barrett center. [3]" ], "subsections": [ { "heading": "Early adenocarcinoma detected in Barrett mucosa", "paragraphs": [ "Treat visible early neoplasia with endoscopic resection to obtain histologic staging and determine whether endoscopic therapy can be curative. Endoscopic resection is first-line curative treatment for well or moderately differentiated T1a esophageal adenocarcinoma in cited guideline summaries; residual Barrett mucosa should then be eradicated to reduce metachronous neoplasia risk. [4][18]" ], "bullets": [] } ], "table": { "caption": "Management branch after expert confirmation of Barrett histology. [1][2][5][18][20]", "columns": [ "Histology or endoscopic phenotype", "Preferred next step", "Key exception or prerequisite" ], "rows": [ [ "Nondysplastic Barrett esophagus", "Endoscopic surveillance. [5]", "Do not use routine eradication therapy in the general nondysplastic population. [20]" ], [ "Indefinite for dysplasia", "Optimize acid suppression; repeat endoscopy in 6 months. [18]", "If repeat biopsies lack definite dysplasia, follow nondysplastic surveillance strategy. [19]" ], [ "Confirmed low-grade dysplasia", "Offer or strongly consider RFA after confirmation on 2 endoscopies and by 2 GI pathologists. [18]", "Surveillance remains a reasonable alternative in selected patients. [5]" ], [ "High-grade dysplasia without visible lesion", "Endoscopic eradication therapy, commonly RFA. [2][3]", "Surveillance is not generally first-line management. [3]" ], [ "High-grade dysplasia or early cancer with visible lesion", "Endoscopic resection first, followed by eradication of residual Barrett mucosa. [2][18]", "Do not rely on ablation alone for a visible lesion. [2]" ] ] } }, { "id": "post-eradication-and-reflux-management", "eyebrow": "Longitudinal care", "heading": "Maintain surveillance after eradication and do not use antireflux surgery for cancer prevention", "intro": "Eradication reduces neoplastic burden but does not eliminate the need for endoscopic follow-up.", "paragraphs": [ "Arrange endoscopic follow-up after endoscopic treatment for Barrett esophagus with dysplasia. During post-eradication examinations, inspect the esophagus and cardia using white light, virtual chromoendoscopy, and near focus to identify recurrent Barrett mucosa or neoplasia. [11][18]", "Continue long-term follow-up after apparent complete eradication because progression or recurrence can occur after endoscopic eradication therapy. [20]", "Do not recommend fundoplication or other antireflux surgery solely to prevent esophageal adenocarcinoma in Barrett esophagus. In a cohort of 33,939 patients followed for up to 32 years, antireflux surgery was not associated with reduced adenocarcinoma risk versus antireflux medication (adjusted hazard ratio 1.9; 95% CI, 1.1-3.5). [8][23]" ], "bullets": [ "Use antireflux surgery for conventional reflux indications rather than as a Barrett cancer-prevention intervention. [8][23]", "Tailor surveillance frequency within recommended intervals to age, sex, family history of esophageal cancer, and smoking history. [18]", "Reassess whether surveillance benefits outweigh procedural risks in patients with substantial comorbidity or limited physiologic reserve. [18]" ], "subsections": [], "table": { "caption": "Longitudinal decisions after Barrett diagnosis or eradication. [8][11][18][20]", "columns": [ "Clinical issue", "Decision", "Rationale" ], "rows": [ [ "After endoscopic treatment for dysplastic Barrett", "Continue endoscopic follow-up. [18]", "Progression or recurrence can occur after eradication therapy. [20]" ], [ "Post-eradication examination", "Inspect esophagus and cardia with white light, virtual chromoendoscopy, and near focus. [11]", "Improve detection of recurrent mucosal abnormality. [11]" ], [ "Considering fundoplication for cancer prevention", "Do not offer solely to reduce adenocarcinoma risk. [8]", "Long-term observational data did not show risk reduction compared with antireflux medication. [8][23]" ] ] } } ], "faq": [ { "question": "Does a patient with an irregular Z-line require Barrett surveillance?", "answer": "No. Columnar-lined esophagus shorter than 1 cm should not undergo routine Barrett surveillance; this finding should not be treated as a surveillance-eligible Barrett segment. [8]" }, { "question": "When should a visible Barrett lesion be ablated?", "answer": "Do not use primary ablation for a visible nodular lesion. Perform endoscopic resection first for diagnosis, staging, and local therapy, then eradicate residual Barrett mucosa when indicated. [2][18]" } ], "references": [ { "number": 1, "title": "National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/6/897", "authors": "gut.bmj.com", "host": "gut.bmj.com" }, { "number": 2, "title": "Utility of ancillary studies in the diagnosis and risk assessment of Barrett’s esophagus and dysplasia | Modern Pathology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41379-022-01056-0", "authors": "www.nature.com", "host": "www.nature.com" }, { "number": 3, "title": "Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma? - Kollmann - 2026 - Annals of the New York Academy of Sciences - Wiley Online Library", "detail": "nyaspubs.onlinelibrary.wiley.com", "url": "https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.70196", "authors": "nyaspubs.onlinelibrary.wiley.com", "host": "nyaspubs.onlinelibrary.wiley.com" }, { "number": 4, "title": "Barrett's Esophagus", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jgh.70166", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com" }, { "number": 5, "title": "Endoscopic eradication therapy for Barrett's... : Current Opinion in ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/co-gastroenterology/fulltext/2020/07000/endoscopic_eradication_therapy_for_barrett_s.16.aspx?Ppt=Article%7Cco-gastroenterology%3A2020%3A07000%3A00016%7C10.1097%2Fmog.0000000000000650%7C", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 6, "title": "Advancements in interventional gastroenterology... : Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202604240-00098", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 7, "title": "Barrett Esophagus - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/nursing-and-health-professions/barrett-esophagus", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0016508523049806", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma | Diseases of the Esophagus | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/dote/article-abstract/19/5/321/2419710", "authors": "academic.oup.com", "host": "academic.oup.com" }, { "number": 10, "title": "AGA Clinical Practice Guideline on Surveillance of Barrett's ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 11, "title": "AGA Clinical Practice Guideline on Endoscopic Eradication Therapy ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(24)00302-0/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 12, "title": "Surveillance in Barrett's Esophagus: Challenges, Progress, ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(23)00103-8/abstract", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 13, "title": "American Gastroenterological Association Medical Position ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(11)00084-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org" }, { "number": 14, "title": "Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10259184", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 15, "title": "American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3258495", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 16, "title": "Barrett’s Esophagus: An Updated Review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9858189", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 17, "title": "Towards screening Barrett’s oesophagus: current guidelines, imaging modalities and future developments", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7519897", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 18, "title": "Recommendations | Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng231/chapter/Recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 19, "title": "[PDF] HTG345 Endoscopic radiofrequency ablation for Barrett's ... - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/htg345/evidence/overview-final-pdf-366535981", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 20, "title": "[PDF] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/htg219/documents/endoscopic-radiofrequency-ablation-for-barretts-oesophagus-with-low-grade-dysplasia-or-no-dysplasia-overview2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 21, "title": "[PDF] Barrett's oesophagus and stage 1 oesophageal adenocarcinoma", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng231/evidence/i-endoscopic-treatment-lowgrade-dysplasia-and-indefinite-dysplasia-pdf-409368094164", "authors": "www.nice.org.uk", "host": "www.nice.org.uk" }, { "number": 22, "title": "Barrett Esophagus: Risk Factors for Progression to Dysplasia and Adenocarcinoma - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1357704", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 23, "title": "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/37690771", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma | WHO FCTC", "detail": "portal-uat.who.int", "url": "https://portal-uat.who.int/fctcapps/fctcapps/fctc/kh/wts/wts-database/microbiome-and-potential-targets-chemoprevention-esophageal", "authors": "portal-uat.who.int", "host": "portal-uat.who.int" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett’s oesophagus and stage I oesophageal adenocarcinoma | Gut", "detail": "gut.bmj.com", "url": "https://gut.bmj.com/content/73/6/897", "authors": "gut.bmj.com", "host": "gut.bmj.com", "snippet": "### 1.5 Managing Barrett’s oesophagus with low-grade dysplasia\n\nClinical evidence from three RCTs (online supplemental table 8) and one observational study63–66 showed a clinically important benefit of radiofrequency ablation (RFA) compared with endoscopic surveillance across all outcomes examined i", "score": 0.56200886 }, { "number": 2, "title": "Utility of ancillary studies in the diagnosis and risk assessment of Barrett’s esophagus and dysplasia | Modern Pathology", "detail": "www.nature.com", "url": "https://www.nature.com/articles/s41379-022-01056-0", "authors": "www.nature.com", "host": "www.nature.com", "snippet": "losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett’s esophagus. Proc. Natl. Acad. Sci. USA 93, 7081–7084 (1996).\"),6 tissue. J. Natl. Cancer Inst. 91, 2087–2095 (1999).\"),7.\"),8.\"),9.\"),10.\"). Because dysplasia is currently the primary clinical biomarker used to identif", "score": 0.60049355 }, { "number": 3, "title": "Antireflux Surgery for Barrett's Esophagus: Where Do We Stand in Preventing Esophageal Adenocarcinoma? - Kollmann - 2026 - Annals of the New York Academy of Sciences - Wiley Online Library", "detail": "nyaspubs.onlinelibrary.wiley.com", "url": "https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/nyas.70196", "authors": "nyaspubs.onlinelibrary.wiley.com", "host": "nyaspubs.onlinelibrary.wiley.com", "snippet": "typically every 6−12 months, unless endoscopic eradication therapy is pursued, which is increasingly favored due to the higher risk of progression. For HGD, surveillance is not generally recommended as first-line management; instead, endoscopic eradication therapy is preferred, but if surveillance i", "score": 0.580091 }, { "number": 4, "title": "Barrett's Esophagus", "detail": "onlinelibrary.wiley.com", "url": "https://onlinelibrary.wiley.com/doi/10.1111/jgh.70166", "authors": "onlinelibrary.wiley.com", "host": "onlinelibrary.wiley.com", "snippet": "Nov 13, 2025 — The ESGE 2017 and 2023 guidelines recommend ER as the first-line, curative treatment for T1a EAC if the tumor is well or moderately ...Read more", "score": 0.47358477 }, { "number": 5, "title": "Endoscopic eradication therapy for Barrett's... : Current Opinion in ...", "detail": "journals.lww.com", "url": "https://journals.lww.com/co-gastroenterology/fulltext/2020/07000/endoscopic_eradication_therapy_for_barrett_s.16.aspx?Ppt=Article%7Cco-gastroenterology%3A2020%3A07000%3A00016%7C10.1097%2Fmog.0000000000000650%7C", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "For nondysplastic Barrett's oesophagus, surveillance alone is recommended. For low-grade dysplasia, both surveillance and ablation are reasonable options and", "score": 0.56489134 }, { "number": 6, "title": "Advancements in interventional gastroenterology... : Medicine", "detail": "journals.lww.com", "url": "https://journals.lww.com/md-journal/_layouts/15/oaks.journals/downloadpdf.aspx?an=00005792-202604240-00098", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "EUS = endoscopic ultrasound, GI = gastrointestinal.\n\n### 3.3. Ablative therapies for early GI cancers\n\nAblative endoscopic therapies provide effective treatment options for early neoplasia and premalignant conditions. Radiofrequency ablation is well established for dysplastic Barrett esophagus and e", "score": 0.39831337 }, { "number": 7, "title": "Barrett Esophagus - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/nursing-and-health-professions/barrett-esophagus", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Title: Barrett Esophagus - an overview | ScienceDirect Topics\nBarrett's esophagus (BE) is an acquired condition resulting from gastroesophageal reflux disease and is a well-established risk factor for esophageal adenocarcinoma (EAC). For a patient with Barrett's esophagus, the risk of developing car", "score": 0.76701033 }, { "number": 8, "title": "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett’s Esophagus", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S0016508523049806", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "to develop recommendations regarding the role of endoscopic surveillance in patients with BE. The clinical domains addressed included: (1) overall role of endoscopic surveillance, (2) surveillance in patients with columnar-lined esophagus <1 cm, (3) optimal imaging modalities, (4) adjunctive samplin", "score": 0.7366474 }, { "number": 9, "title": "Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma | Diseases of the Esophagus | Oxford Academic", "detail": "academic.oup.com", "url": "https://academic.oup.com/dote/article-abstract/19/5/321/2419710", "authors": "academic.oup.com", "host": "academic.oup.com", "snippet": "# Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma *Available for Purchase*. G. Casson, Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma, *Diseases of the Eso", "score": 0.7300017 }, { "number": 10, "title": "AGA Clinical Practice Guideline on Surveillance of Barrett's ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(25)06013-5/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "A structured biopsy protocol includes targeted biopsies from any visible lesions and random 4-quadrant biopsies every 2 cm if no history of dysplasia and every", "score": 0.5715041 }, { "number": 11, "title": "AGA Clinical Practice Guideline on Endoscopic Eradication Therapy ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(24)00302-0/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "When performing surveillance post EET, the esophagus and cardia should be examined under white light and virtual chromoendoscopy with near focus, particularly", "score": 0.52627033 }, { "number": 12, "title": "Surveillance in Barrett's Esophagus: Challenges, Progress, ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(23)00103-8/abstract", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "by PG Iyer · 2023 · Cited by 30 — Endoscopic surveillance of Barrett's esophagus, aiming to detect prevalent dysplasia and adenocarcinoma, followed by effective endoscopic ...Read more", "score": 0.41094592 }, { "number": 13, "title": "American Gastroenterological Association Medical Position ...", "detail": "www.gastrojournal.org", "url": "https://www.gastrojournal.org/article/S0016-5085(11)00084-9/fulltext", "authors": "www.gastrojournal.org", "host": "www.gastrojournal.org", "snippet": "Endoscopic surveillance has become the standard of practice for patients with Barrett's esophagus based on the unproven assumption that the practice will reduce", "score": 0.3955783 }, { "number": 14, "title": "Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10259184", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "#### Summary of evidence.\n\nThe Seattle protocol, first described in 1993, consists of careful\nvisual inspection of the Barrett’s segment with biopsies of any\nendoscopically visible lesions, followed by 4 quadrant biopsies at intervals\n≤2 cm from the level of the lower esophageal sphincter to the\nsqu", "score": 0.6615081 }, { "number": 15, "title": "American Gastroenterological Association Technical Review on the Management of Barrett's Esophagus - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3258495", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "### Should Chromoendoscopy or “Electronic Chromoendoscopy” Be Used to Enhance the Detection of Metaplasia and Dysplasia in Barrett's Esophagus?\n\nThe Seattle biopsy protocol for endoscopic surveillance in Barrett's esophagus, which involves 4-quadrant biopsy sampling of every 1 to 2 cm of the columna", "score": 0.65359193 }, { "number": 16, "title": "Barrett’s Esophagus: An Updated Review", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9858189", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "## \n\nWide-area transepithelial sampling (WATS) is a three-dimensional (3D), computer-assisted technique which has been used as an adjunct to traditional forceps biopsy. The Seattle protocol has certain limitations, including sampling bias, limited sampling area, low compliance, and sampling variabil", "score": 0.6271529 }, { "number": 17, "title": "Towards screening Barrett’s oesophagus: current guidelines, imaging modalities and future developments", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7519897", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "### Surveillance\n\nThe primary aim of surveillance of Barrett’s oesophagus is to identify dysplasia and malignancy before distant disease has advanced. OAC usually presents with advanced disease as a result of early lymphovascular submucosal invasion . OGD remains the primary method of surveillance u", "score": 0.5928793 }, { "number": 18, "title": "Recommendations | Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management | Guidance | NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng231/chapter/Recommendations", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "#### 1.5.2\n\nOffer endoscopic ablation of any residual Barrett's oesophagus to people with high-grade dysplasia after treatment with endoscopic resection.\n\n#### 1.5.3\n\nOffer radiofrequency ablation to people with low-grade oesophageal dysplasia diagnosed from biopsies taken at 2 separate endoscopies.", "score": 0.6864757 }, { "number": 19, "title": "[PDF] HTG345 Endoscopic radiofrequency ablation for Barrett's ... - NICE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/htg345/evidence/overview-final-pdf-366535981", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "a diagnosis of indefinite for dysplasia should be managed with optimisation of antireflux medication and repeat endoscopy in 6 months. If no definite dysplasia is found on subsequent biopsies, then the surveillance strategy should follow the recommendation for non-dysplastic Barrett’s oesophagus (Re", "score": 0.6554468 }, { "number": 20, "title": "[PDF] NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/htg219/documents/endoscopic-radiofrequency-ablation-for-barretts-oesophagus-with-low-grade-dysplasia-or-no-dysplasia-overview2", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "available evidence is insufficient to show that RFA plus surveillance achieves a better net health outcome than surveillance alone among patients with non-dysplastic or low-grade dysplastic Barrett’s esophagus. The body of evidence on disease progression is too small and of a too short duration to p", "score": 0.6496014 }, { "number": 21, "title": "[PDF] Barrett's oesophagus and stage 1 oesophageal adenocarcinoma", "detail": "www.nice.org.uk", "url": "https://www.nice.org.uk/guidance/ng231/evidence/i-endoscopic-treatment-lowgrade-dysplasia-and-indefinite-dysplasia-pdf-409368094164", "authors": "www.nice.org.uk", "host": "www.nice.org.uk", "snippet": "study showed a clinically important benefit of RFA compared to endoscopic surveillance across all outcomes examined, except for complications. RCT evidence showed a clinically important benefit of RFA over endoscopic surveillance for complete eradication of dysplasia and complete eradication of inte", "score": 0.58976424 }, { "number": 22, "title": "Barrett Esophagus: Risk Factors for Progression to Dysplasia and Adenocarcinoma - PMC", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1357704", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "The observations in this study suggest that low-grade dysplasia is the only available, clinically useful risk factor that permits stratification of the surveillance intervals according to the risk of the individual patient. Our results further suggest that successful antireflux surgery protects the ", "score": 0.70580584 }, { "number": 23, "title": "Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus - PubMed", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/pubmed/37690771", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Antireflux Surgery Versus Antireflux Medication and Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus - PubMed\nSkip to main page content. An official website of the United States government. The **https://** ensures that you are connecting to the official website and that", "score": 0.6844544 }, { "number": 24, "title": "Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma | WHO FCTC", "detail": "portal-uat.who.int", "url": "https://portal-uat.who.int/fctcapps/fctcapps/fctc/kh/wts/wts-database/microbiome-and-potential-targets-chemoprevention-esophageal", "authors": "portal-uat.who.int", "host": "portal-uat.who.int", "snippet": "Title: Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma | WHO FCTC\nLR: 20160315; CI: Published by Elsevier Inc.; GR: R01 CA159036/CA/NCI NIH HHS/United States; GR: R01CA159036/CA/NCI NIH HHS/United States; GR: R03 CA159414/CA/NCI NIH HHS/United States; GR: R03CA15941", "score": 0.6690754 } ], "publishedAt": "2026-09-16T00:42:55.859852+00:00", "updatedAt": "2026-09-16T00:42:55.859852+00:00", "readingMinutes": 4, "slug": "barrett-esophagus" }